Pfizer asks FDA to authorize bivalent COVID-19 vaccine for children age 5-11
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for emergency use in children aged 5-11. Pfizer also announced a clinical study to evaluate the safety and effectiveness of different dosing regimens for the bivalent vaccine in children aged 6 months through 11.
The FDA recently authorized, and the Centers for Disease Control recommended, a booster dose of the Pfizer bivalent vaccine for Americans aged 12 and older. The bivalent boosters protect against the most recently circulating omicron variants as well as the original virus strain.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…